Ingenuity Systems and Life Technologies Introduce Complete End-to-End Solution for Real-Time PCR Gene Expression Analysis
Ingenuity® iReport™ for Real-Time PCR, optimized for TaqMan®Gene Expression Assays provides a quick and reliable way for bench biologists to understand gene expression data.
Redwood City, CA – April 2, 2012 – Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, and Life Technologies Corporation (NASDAQ: LIFE) today announced Ingenuity iReport for Real-Time PCR optimized for TaqMan®Gene Expression Assays. The new solution is an interactive report that extends analysis beyond Ct or fold-changes to an accurate and dynamic view of the biological information most relevant to a gene expression experiment.
Dr. Mikael Kubista, founder of TATAA Biocenter in Göteborg, Sweden, studies gene expression in single-cell astrocytes. "In our research, we have developed specific strategies for analyzing single-cell data and defining important sets of genes based on correlation between the genes' expressions as measured by qPCR. Uploading this data to iReport, we were able to immediately see the biology underlying our statistical results, and develop new hypotheses based on the differentially expressed pathways involved in our single cell experiments."
In contrast to time consuming manual searches for relevant publications and gene relationships, Ingenuity iReport for Real-Time PCR provides a more rapid and comprehensive understanding of pathways, processes, and diseases relevant to gene expression results. With its engaging and intuitive design, iReport for Real-Time PCR can be used by bench scientists to easily and accurately understand the biological meaning of their experiment within minutes. Peer-reviewed literature is cited throughout the report, allowing the underlying evidence to be easily accessed and referenced. iReport for Real-Time PCR has been optimized for several TaqMan Gene Expression assay formats, including TaqMan Array Card and OpenArray® file types.
"Ingenuity iReport for Real-Time PCR is the perfect complement to our industry-leading PCR portfolio," said Chris Linthwaite, Head of Genetic Analysis, Life Technologies. "Our Real-Time PCR products produce data that is highly sensitive and specific with a broad dynamic range and at a cost-effective price per data point. Integrating iReport into our portfolio will enable our customers to accelerate the pace of scientific discovery – quickly connecting data to biological meaning."
"Life Technologies is focused on creating a complete user experience for their PCR customers," said Jake Leschly, CEO of Ingenuity Systems. "With iReport for Real-Time PCR we have designed a revolutionary product that will help researchers identify relevant biology from gene expression experiments and we have gone to great lengths to design a fully integrated marketing, e-commerce and customer support experience to ensure that the combined Real- Time PCR iReport experience is as seamless and easy as the products themselves."
Free iReport for a Limited Time
To learn more about Ingenuity iReport for Real-Time PCR or to receive a free report, please go to www.lifetechnologies.com/ireport. Additional product information will also be available from Ingenuity (booth 1602) and Life Technologies (booth 4419) at the American Association of Cancer Research (AACR) meeting, March 31-April 4th, in Chicago, Illinois.
About Ingenuity® Systems
Ingenuity Systems is a leading provider of information and analysis solutions for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. For more information visit: www.ingenuity.com.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.